Mark Mulligan
Infectious Disease · Atlanta, GANPI 1720019920
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,430 of the $4,468 with a category attached, or 99.1%. Pfizer accounts for 62.0% of it on its own, with 1 other manufacturer making up the rest. 2022 is the largest year on record at $2,730, more than ten times the $18 reported in 2019.
Across 7 payments — averaging $638.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Merck$2K
Across 308 payments — averaging $14,846 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.8M
- Sanofi Pasteur Inc.$600K
- Eli Lilly$106K
- Sanofi US Services Inc.$40K
What the payments were for
- Consulting fees$4,43099%
- Food & beverage$180%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,468 in reported general payments places this provider in the 75th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Atlanta
- Zandraetta Tims-CookAtlanta$848K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Colleen KraftAtlanta$103K
- Walter OrensteinAtlanta$78K
- Nadine RouphaelAtlanta$66K
- Kimberly WorkowskiAtlanta$53K
- Bernard BransonAtlanta$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.